{"id":"W2127385754","doi":"10.1016/s1470-2045(14)70030-0","title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Sorafenib; Open label; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Second line treatment; Hepatocellular carcinoma; Clinical trial; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007454352,0.0003335291,0.001647583,0.00007919039,0.000123021,0.00001848289,0.0003228727,0.00009614835,0.00006720136],"category_scores_gemma":[0.000135181,0.0001763406,0.0001079672,0.0001400423,0.0001844906,0.00007698567,0.0000490196,0.000117442,0.000009518396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003284307,"about_ca_system_score_gemma":0.0003721016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001168396,"about_ca_topic_score_gemma":0.0001087355,"domain_scores_codex":[0.9975691,0.000676231,0.0005713541,0.0004325192,0.0002708211,0.0004799904],"domain_scores_gemma":[0.9971031,0.001196851,0.000494917,0.0007708613,0.0002389098,0.0001953629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9745477,0.01324056,0.0002897436,0.00007542076,0.0004476783,0.00003468471,0.0004979447,0.00002002155,0.004245106,0.0001166698,0.0007065658,0.005777896],"study_design_scores_gemma":[0.7822585,0.1900264,0.0005785591,0.000009508261,0.00182375,0.000005515016,0.00005801852,0.0005331376,0.0177517,0.00006580775,0.006740255,0.0001489242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884589,0.0001538662,0.0002611908,0.0006679976,0.000352197,0.007423875,0.0001927617,0.00003553628,0.002453664],"genre_scores_gemma":[0.9897204,0.00001685188,0.00709301,0.0002212846,0.0005820067,0.001118222,0.0008920076,0.00004688245,0.0003093338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1922893,"threshold_uncertainty_score":0.719096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1290889388003442,"score_gpt":0.3833123518399601,"score_spread":0.2542234130396159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}